Chinese Pharmacopoeia Sterility Test: Principles, Methods, and Regulatory Compliance Guide

The sterility test specified in the Chinese Pharmacopoeia (ChP General Chapter 1101) is a critical release assay that verifies the absence of viable aerobic bacteria, anaerobic bacteria, and fungi in sterile pharmaceutical products. This technical article provides a comprehensive overview of the Chinese Pharmacopoeia sterility test experiment, covering culture media, method suitability validation, membrane filtration and direct inoculation procedures, result interpretation, and practical industry applications.

Technical Overview

The sterility test is a compendial quality control assay described in Volume IV of the Chinese Pharmacopoeia (2020 Edition), General Chapter 1101, "Sterility Test." It is designed to determine whether a sterile product is free from viable microorganisms by introducing the sample into two types of culture media, or by filtering the sample through a membrane that is subsequently incubated in those media, followed by incubation and observation for microbial growth.

The Chinese Pharmacopoeia sterility test is technically aligned with the major international compendial methods, including USP Chapter 71, Ph. Eur. Section 2.6.1, and JP 4.06. This alignment facilitates mutual acceptance of test data and supports regulatory submissions for both the domestic Chinese market and international export.

Key features of the sterility test experiment include:

• Two compendial procedures: the membrane filtration method and the direct inoculation method.
• Two culture media: Fluid Thioglycollate Medium for aerobic and anaerobic bacteria, and Tryptic Soy Broth (soybean-casein digest medium) for aerobic bacteria and fungi.
• A minimum incubation period of not less than 14 days.
• A mandatory method suitability test to demonstrate that the product does not inhibit microbial growth.
• Positive and negative controls to confirm test validity.

Because the sterility test is probabilistic and examines only a sample fraction of a batch, it cannot by itself guarantee the sterility of the entire batch. The test must be supported by a validated aseptic manufacturing process, media fill simulations, and a comprehensive Good Manufacturing Practice (GMP) control system. The test itself must be performed under aseptic conditions in a controlled environment, typically a Grade A laminar airflow cabinet or isolator with a Grade B background, as required by Chinese GMP.

Testing Samples

The Chinese Pharmacopoeia sterility test applies to a wide range of products that are required to be sterile. Typical sample categories include the following.

Sterile Pharmaceutical Preparations

This category includes small-volume and large-volume parenteral injections, intravenous infusions, powders and lyophilized powders for injection (tested after reconstitution with the appropriate diluent), ophthalmic solutions and ointments, intrathecal preparations, irrigating solutions, and other preparations labeled as sterile.

Biological Products

Vaccines, blood products such as human albumin and immunoglobulins, recombinant proteins, monoclonal antibodies, and other biologics are subject to sterility testing as part of release specifications. For advanced therapy products with limited shelf life, testing schedules must be coordinated to ensure that the 14-day observation period is completed appropriately.

Medical Devices and Surgical Materials

Absorbable sutures, implants, surgical dressings, absorbable hemostatic materials, catheters, and other sterile devices are tested by direct inoculation, by immersion in culture medium, or by membrane filtration of the rinse fluid recovered after agitation or sonication of the device.

Sterile Raw Materials and Excipients

Sterile active pharmaceutical ingredients, such as sterile antibiotic substances, and excipients intended for use in sterile formulations are also subjected to the sterility test, usually by the membrane filtration method.

Testing Items

The sterility test experiment comprises several defined test items, each of which must be executed and documented according to pharmacopoeial requirements.

• Aerobic bacterial detection using Fluid Thioglycollate Medium and Tryptic Soy Broth.
• Anaerobic bacterial detection using Fluid Thioglycollate Medium.
• Fungal detection, covering both yeasts and filamentous fungi, using Tryptic Soy Broth.
• Method suitability verification, also known as the bacteriostasis and fungistasis test, which demonstrates that the product itself does not suppress the growth of challenge microorganisms.
• Culture media quality control, including growth promotion testing, media sterility testing, and confirmation of indicative properties.
• Positive control and negative control testing to confirm the reliability of each test run.

Growth promotion testing requires that each batch of medium support vigorous growth of defined reference strains inoculated at levels not exceeding 100 colony-forming units, with growth comparable to that obtained with a previously qualified batch of medium. Media that fail growth promotion, or that show turbidity or contamination before use, must not be used for the test.

Testing Methods

Culture Media and Incubation Conditions

Fluid Thioglycollate Medium is primarily intended for the cultivation of anaerobic bacteria, although it also supports the growth of aerobic bacteria. It is incubated at 30 to 35 degrees Celsius. The medium contains an oxidation-reduction indicator, and any oxidized upper layer should not exceed the limits defined in the monograph; freshly prepared or properly stored medium must be used to maintain anaerobic conditions in the lower portion of the tube.

Tryptic Soy Broth, also referred to as soybean-casein digest medium, is intended for the cultivation of aerobic bacteria and fungi and is incubated at 20 to 25 degrees Celsius. All media must be sterilized by a validated cycle, and their performance must be verified before use.

Both media are incubated for not less than 14 days, with visual examination for microbial growth at defined intervals, commonly on days 3, 7, and 14, and at the conclusion of the incubation period.

Method Suitability Test

Before the sterility test is performed on a product, it must be demonstrated that the product does not possess antimicrobial activity under the conditions of the test. The method is challenged with low-level inocula, not more than 100 colony-forming units, of the following reference strains from the National Center for Medical Culture Collections:

• Staphylococcus aureus, tested in Fluid Thioglycollate Medium.
• Pseudomonas aeruginosa, tested in Fluid Thioglycollate Medium.
• Clostridium sporogenes, tested in Fluid Thioglycollate Medium.
• Bacillus subtilis, tested in Fluid Thioglycollate Medium and in Tryptic Soy Broth.
• Candida albicans, tested in Tryptic Soy Broth.
• Aspergillus brasiliensis, tested in Tryptic Soy Broth.

The growth observed in the presence of the product must be comparable to that of the positive control within the prescribed time limits, typically 3 days for bacteria, 5 days for Candida albicans, and 7 days for Aspergillus brasiliensis. If growth is inhibited, the method must be modified, for example by increasing the volume of rinsing fluid, adding a neutralizing agent such as penicillinase for beta-lactam antibiotics, or using dilution or membrane filtration with validated rinsing, until suitable recovery is achieved.

Membrane Filtration Method

The membrane filtration method is preferred whenever the product can be filtered. The sample is passed aseptically through a membrane filter with a nominal pore size of 0.45 micrometers and a diameter of approximately 50 millimeters, or through a closed, pre-sterilized filtration canister system. After filtration, the membrane is rinsed with a validated rinsing fluid, typically three successive 100 milliliter portions of 0.1 percent peptone water, with or without 0.5 percent polysorbate 80, to remove residual antimicrobial substances.

The membrane is then transferred aseptically into vessels containing the culture media, or the media are introduced into the closed canister system. One portion is incubated in Fluid Thioglycollate Medium at 30 to 35 degrees Celsius and one in Tryptic Soy Broth at 20 to 25 degrees Celsius, each for not less than 14 days. The membrane filtration method is particularly suitable for antibiotics, preservative-containing formulations, and large-volume products because the antimicrobial agents are substantially removed by rinsing.

Direct Inoculation Method

The direct inoculation method is used for products that cannot be filtered, such as ointments, viscous suspensions, non-aqueous preparations, and solid devices. A measured quantity of the product is transferred directly into vessels of culture medium. The volume of product inoculated generally must not exceed 10 percent of the volume of the medium, unless otherwise justified and validated, so that the nutritive and neutralizing capacity of the medium is not compromised. Oily preparations may require the addition of a suitable emulsifier, and devices may be immersed directly in the medium. The vessels are then incubated under the same conditions described above.

Sampling Plan

The number of containers sampled and the quantity taken from each container are prescribed in the tables of General Chapter 1101 and depend on the batch size and the fill volume of the product. For example, batches containing not more than 100 containers require sampling of 10 percent of the containers or 4 containers, whichever is greater; batches of more than 100 but not more than 500 containers require 10 containers; and batches of more than 500 containers require 2 percent or 20 containers, whichever is less. The quantity taken from each container depends on the volume of product in the container, ranging from the entire contents for small-volume containers to a defined minimum volume for larger containers.

Controls

Positive controls are prepared by inoculating the media with the designated reference strains to confirm that the media and incubation conditions support growth. Negative controls consisting of medium alone are incubated alongside the test to monitor the sterility of the media and the adequacy of aseptic technique. Growth in a negative control invalidates the test and requires an investigation.

Observation and Interpretation of Results

The vessels are examined periodically for turbidity or other evidence of microbial growth. If growth is observed, the presence of microorganisms is confirmed by transfer to fresh media or by microscopic examination. The product passes the sterility test if no microbial growth is observed in either medium at the end of the incubation period.

If growth is observed, the test is not automatically failed. The result is considered invalid, and the test may be repeated with the same number of sample units, only if the growth can be attributed to clearly identified causes such as faulty aseptic technique, contamination of the materials or equipment used in the test, or growth in the negative controls. If the investigation demonstrates that the contamination is attributable to the product, or if growth is again observed on repeat testing under valid conditions, the batch fails the sterility test.

Applications

The Chinese Pharmacopoeia sterility test experiment is applied throughout the life cycle of sterile products across the pharmaceutical, biotechnology, and medical device industries.

• Batch release testing of sterile drug products prior to commercial distribution.
• Regulatory dossier preparation, including quality documentation submitted to the National Medical Products Administration and to international authorities for export products.
• Validation of holding times for bulk sterile solutions prior to filling.
• Stability programs confirming the maintenance of sterility throughout the product shelf life.
• Support of aseptic process validation and investigation of media fill deviations or environmental monitoring excursions.
• Contract laboratory testing services for manufacturers lacking in-house sterility testing suites.
• Testing of antibiotic and preservative-containing products using validated neutralization and membrane filtration strategies.

Laboratories performing the test must maintain qualified cleanroom facilities, validated sterilization cycles, calibrated incubators, traceable reference cultures, comprehensive environmental monitoring programs, and trained personnel, together with complete documentation to satisfy GMP inspection expectations.

FAQ

What is the minimum incubation period for the Chinese Pharmacopoeia sterility test?

Both Fluid Thioglycollate Medium and Tryptic Soy Broth must be incubated for not less than 14 days, with observations for growth recorded at defined intervals during this period.

What is the difference between the membrane filtration method and the direct inoculation method?

The membrane filtration method passes the sample through a 0.45 micrometer membrane, which is then rinsed and incubated in the media, effectively removing antimicrobial residues. The direct inoculation method introduces the product directly into the media and is reserved for products that cannot be filtered, such as ointments, suspensions, and solid devices.

Why is the method suitability test mandatory?

Many products contain antimicrobial, preservative, or fungistatic ingredients that could suppress the growth of contaminating organisms and produce a false negative result. The method suitability test demonstrates, using low-level challenge inocula of six reference strains, that the chosen test conditions allow detectable growth despite the presence of the product.

Which microorganisms are used as challenge strains?

The standard strains are Staphylococcus aureus, Pseudomonas aeruginosa, Clostridium sporogenes, Bacillus subtilis, Candida albicans, and Aspergillus brasiliensis, obtained from recognized culture collections such as the CMCC.

What happens if microbial growth is observed during the test?

The growth must be confirmed and identified. The test is judged invalid only if a specific laboratory or material-related cause is demonstrated, in which case the test is repeated with the same number of units. If no such cause exists, or if growth recurs on retesting, the product fails the sterility test and the batch must be rejected.

Is the Chinese Pharmacopoeia sterility test accepted internationally?

The method is technically aligned with USP Chapter 71, Ph. Eur. Section 2.6.1, and JP 4.06. Data generated in a GMP-compliant laboratory using the Chinese Pharmacopoeia procedure are therefore widely accepted in support of both domestic registrations and international export documentation.